0000874015-23-000067.txt : 20230119
0000874015-23-000067.hdr.sgml : 20230119
20230119202140
ACCESSION NUMBER: 0000874015-23-000067
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230117
FILED AS OF DATE: 20230119
DATE AS OF CHANGE: 20230119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'NEIL PATRICK R.
CENTRAL INDEX KEY: 0001564926
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 23538712
MAIL ADDRESS:
STREET 1: C/O ISIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2023-01-17
0
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001564926
O'NEIL PATRICK R.
2855 GAZELLE COURT
CARLSBAD
CA
92010
0
1
0
0
EVP CLO & General Counsel
Common Stock
2023-01-17
4
M
0
21871
0.0
A
56515
D
Common Stock
2023-01-18
4
S
0
7836
39.4946
D
48679
D
Restricted Stock Unit
0.0
2023-01-17
4
M
0
21871
0.0
D
Common Stock
21871
47655
D
Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.44163 to $39.54855 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Patrick R. O'Neil
2023-01-19